Establishment of Patient-Derived Organoids and a Characterization-Based Drug Discovery Platform for Treatment of Pancreatic Cancer

Patient-derived organoids were established from pancreatic tumor surgical specimens, and the mutations were examined using a panel sequence. Expression of markers was assessed by PCR, immunoblotting, and immunohistochemistry.